Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study
复制标题
DOI：
10.1038/s41598-020-70743-2
复制
发表时间：
2020-08-13
影响因子：
4.6
通讯作者：
Ishizawa, Keisuke
中科院分区：
文献类型：
--
作者：
Okada, Naoto;Matsuoka, Rie;Ishizawa, Keisuke
免疫检查点抑制剂（ICIs）通过激活宿主免疫力来引发抗肿瘤作用并引起免疫相关不良事件（irAE）。 ICI相关间质性肺疾病（ICI-ILD）是一种难以治疗的致命性irAE；而且，肺癌患者的发病率相对较高。因此，早期ICI-ILD检测和干预对于患者安全非常重要。然而，ICI-ILD的风险评估方法尚未建立，ICI-ILD发生的预测困难。我们研究的目的是确定与 ICI-ILD 相关的危险因素。为此，我们回顾性分析了2016年4月至2019年12月期间在德岛大学医院首次接受ICI并完成治疗的102例肺癌患者。 19 名患者患有所有级别的 ICI-ILD，10 名患者患有≥ 3 级 ICI-ILD。 ≥3级ICI-ILD患者的30天死亡率是所有患者中最高的（P=2和≥50包年分别是≥3级和所有级别ICI-ILD的独立危险因素。总的来说，我们的研究为预测ICI-ILD的发生提供了见解。
Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD) is a fatal irAE that is difficult to treat; moreover, its incidence is relatively higher in patients with lung cancer. Therefore, early ICI-ILD detection and intervention are important for patient safety. However, a risk assessment method for ICI-ILD has not been established and the prediction of ICI-ILD occurrence is difficult. The aim of our study was to identify the risk factors associated with ICI-ILD. To this end, we retrospectively analysed 102 patients with lung cancer who first received ICI and completed the treatment between April 2016 and December 2019 at Tokushima University Hospital. Nineteen patients had all grades of ICI-ILD and 10 had grade >= 3 ICI-ILD. The 30-day mortality rate of patients with grade >= 3 ICI-ILD was the highest among all patients (P= 2 and >= 50 pack-year were independent risk factors of ICI-ILD of grade >= 3 and all grades, respectively. Overall, our study provides insights to predict ICI-ILD occurrence.